Loading…
CTS Corporation
$1.7B
Market Cap
19.6
P/E
1.14
PEG
11.7%
ROCE
12.1%
ROE
0.14
D/E
15.3%
OPM
-16.5%
% from 52W High
61
α RS
🔍 CTS is showing a notable setup because it matches 2 of 37 tracked screener presets and RS Rating is 61. Net: Partial signal stack, not a recommendation. ? Conviction RS Rating
Sources
Conviction 2/37 · RS Rating 61
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for CTS including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

CTS Corporation designs, manufactures, and sells sensors, connectivity components, and actuators in North America, Europe, and Asia.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding CTS
View All Superinvestors →
Manager Shares Value % of Fund Period
Jim Simons Renaissance Technologies LLC 388.4K $18.5M 0.03% Mar 2026
Steve Cohen Point72 Asset Management 14.1K $672K 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific ↑ Improving 4 quarters Full tone analysis in Intelligence →
📊 MIXED CTS Q1 2026 sales $139M (+11%), diversified up 18%, adj. EPS $0.62
Revenue & Profitability
Revenue was $139M, up 11% year-over-year and up 1% sequentially. Adjusted gross margin was 39.5%, up 250 bps. Adjusted diluted EPS was $0.62 compared to $0.44 in the prior year. Operating cash flow was $17M in the quarter. Book-to-bill ratio was 1.1.
Outlook
Management expects solid demand in diversified end markets for 2026, with medical momentum continuing and aerospace/defense benefiting from backlog and normalized government funding. Industrial OEM and distribution sales are expected to remain solid. Transportation volumes are expected to be down due to geopolitical uncertainties and softening global light vehicle forecasts (NA 15M, Europe 16-17M, China 32M). Commercial vehicle demand is anticipated to improve in the second half. Full-year 2026 guidance: sales $560M-$580M, adjusted EPS $2.35-$2.45.
Growth Drivers
Medical growth is driven by robust demand in therapeutics (aesthetics) and diagnostics (ultrasound), with expanded capacity and double-digit sales growth expected. Aerospace & defense growth is supported by a strong pipeline, a $20M underwater hull penetrator win, and new RF filter customers. Industrial growth benefits from recovery in OEM and distribution demand, with wins in heat pumps, flow meters, and printing. Transportation growth includes new wins in sensors (accelerometer, current sensing) and foot controls across multiple geographies, plus the next-generation Smart Actuator launch.
Balance Sheet & CapEx
Not discussed in this earnings call. (No specific CapEx guidance or investment amounts provided; only a mention of slightly higher CapEx in Q1 due to timing.)
Margins
Adjusted gross margin expanded 250 bps year-over-year to 39.5%, driven by operational improvements and favorable end-market mix. The company faces cost pressures from Section 232 tariffs, precious metal inflation, and higher oil-derived costs (resin, epoxy, transportation). Management is partnering with customers and suppliers to make the impact cost neutral, though short-term timing effects may occur. The full-year tax rate is expected to be 21%-23%.
Key Risks
Geopolitical conflicts could impact second-half economic conditions. Supply chain risks include petroleum-based products (resin) and rare earth metals/semiconductors. Section 232 tariff changes on steel and aluminum create cost headwinds. Light vehicle production is forecasted to soften. Management highlighted the need to monitor potential cost increases and adapt with agility.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-28
Q2 2026 saw 7% revenue growth to $145M, record margins, and strong diversified end market performance, offsetting transportation declines. Full-year guidance was raised, with robust cash flow and new business wins supporting a positive outlook.
Q1 2026 Q1 2026 2026-04-29
First quarter sales rose 11% year-over-year, led by strong growth in diversified end markets and medical, with gross margin expanding 250 basis points. Full-year guidance was narrowed, and capital allocation remains balanced between growth, acquisitions, and shareholder returns.
Q4 2025 Q4 2025 2026-02-10
Q4 2025 saw 9% revenue growth and margin expansion, led by strong medical, industrial, and defense performance, while transportation remained flat but secured major new business. 2026 guidance projects continued growth in diversified markets, with sales of $550–$580 million and EPS of $2.30–$2.45.
Q3 2025 Q3 2025 2025-10-28
Q3 sales rose 8% year-over-year to $143 million, with strong growth in diversified end markets and margin expansion. Transportation sales declined, but new product wins and a $5 million naval contract boosted outlook. Full-year guidance narrowed, with EPS impacted by tax changes.
Q2 2025 Q2 2025 2025-07-24
Q2 2025 saw 4% revenue growth and margin expansion, driven by strong diversified end markets and operational execution. Medical, aerospace, and industrial segments grew, while transportation faced headwinds from China and tariffs. Guidance for 2025 was reaffirmed.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.